Fig. 3From: Heterogeneity of the tumor immune microenvironment and its clinical relevanceStrategies to overcome immunological heterogeneity-related resistance to therapies. Selective outgrowth of resistant clones to traditional therapeutic paradigms. Survived clones from initial anti-tumor treatment contribute to drug resistance. Alternatively, boosting immunogenic microenvironment with novel therapies contribute to overcome drug resistanceBack to article page